Sign inJoin waitlistJoin the waitlist

Afshin Dowlati

Associate Director for Clinical Research, Case Comprehensive Cancer Center · Case Western Reserve University

Credentials: · · · ·

History

Program Manager · New York Presbyterian Hospital
Present
Thoracic Oncology Program · Case Western Reserve University/University Hospitals Cleveland Medical Center
Present
Center for Cancer Drug Development · Case Western Reserve University/University Hospitals Cleveland Medical Center
Present

Internal Medicine
Case Western Reserve University/University Hospitals Cleveland Medical Center
1998–2000
Hematology and Medical Oncology
Case Western Reserve University/University Hospitals Cleveland Medical Center
1996–1998
Université de Liège Faculté de Médecine
1988–1992

Research

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
New England Journal of Medicine · 2006 · 4,732 citations
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
New England Journal of Medicine · 2018 · 2,193 citations
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2,…
The Lancet Oncology · 2015 · 1,216 citations

Scot Remick
32 papers
NS
Neelesh Sharma
14 papers
MC
Matthew Cooney
13 papers · 3 as a fellow
Charles Rudin
12 papers
Melinda Hsu
11 papers · 1 as a fellow
Mitchell Machtay
11 papers
Stanton Gerson
11 papers
Tithi Biswas
11 papers
Balazs Halmos
10 papers
Joseph Bokar
10 papers
NL
Nathan Levitan
10 papers
Smitha Krishnamurthi
10 papers

Grants

Case Comprehensive Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $5.4M · Case Western Reserve University
1997–2030
Lung Cancer in East Africa and the Relationship to HIV-1 Infection: Epidemiology, Molecular Characterization and Imaging
National Cancer Institute · U54
Project lead · $541.5K · Case Western Reserve University
2020–2026
Identification and Targeting of Chemotherapy Refractory Small Cell Lung Cancer
National Cancer Institute · R21
Contact PI · $377.6K · Case Western Reserve University
2018–2021
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis
National Cancer Institute · U01
Contact PI · $5M · Case Western Reserve University
1994–2015

Clinical trials

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
Principal investigator · Active not recruiting · Phase 2
National Cancer Institute (NCI)
2022–2027
Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC
Principal investigator · Completed · Phase 2
Case Comprehensive Cancer Center
2020–2026
Study of Oral PQR309 in Patients With Advanced Solid Tumors
Principal investigator · Completed · Phase 1
PIQUR Therapeutics AG
2019
A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm
Principal investigator · Completed · Phase 1
Incuron
2013–2019